Moderna (MRNA) Other Working Capital Changes (2018 - 2026)

Moderna (MRNA) has reported Other Working Capital Changes for 9 consecutive years, with -$16.0 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Other Working Capital Changes fell 108.16% year-over-year to -$16.0 million in Q2 2026; TTM through Jun 2026 was -$373.0 million, a 1765.0% decrease from a year earlier, with the FY2025 full-year figure at -$153.0 million, down 5.52% from the prior year.
• Other Working Capital Changes was -$16.0 million for Q2 2026 at Moderna, up from -$54.0 million in the prior quarter.
• Over five years, Other Working Capital Changes peaked at $179.0 million in Q2 2024 and troughed at -$1.6 billion in Q2 2022.
• A 5-year average of -$364.4 million and a median of -$177.0 million in 2023 frame the typical range for Other Working Capital Changes.
• Across the five-year window, Other Working Capital Changes surged 3350.0% in 2022 and plunged 666.67% in 2025, its largest moves.
• Over 5 years, Other Working Capital Changes stood at $1.6 billion in 2022, then sank by 164.82% to -$1.0 billion in 2023, then surged by 71.65% to -$292.0 million in 2024, then rose by 18.84% to -$237.0 million in 2025, then jumped by 93.25% to -$16.0 million in 2026.
• The last three Other Working Capital Changes figures came in at -$16.0 million (Q2 2026), -$54.0 million (Q1 2026), and -$237.0 million (Q4 2025), per Business Quant data.